Eli Lilly Usa covid-19 2020 patient Eli Lilly Usa

Combo monoclonal antibody drugs may lower coronavirus loads

Reading now: 978
www.cidrap.umn.edu

Mildly to moderately ill COVID-19 adult outpatients given a combination of the monoclonal antibodies bamlanivimab and etesevimab early in the disease had significantly lower viral loads at day 11 than those who received a placebo, but a similar effect was not seen in those given bamlanivimab alone, a study published today in JAMA finds.Bamlanivimab manufacturer Eli Lilly sponsored the double-blind phase 2/3 BLAZE-1 clinical trial, which involved 533 COVID-19 patients at 49 US medical centers.

The goal was to assess the antispike neutralizing antibodies' effects on viral loads of SARS-CoV-2, the virus that causes COVID-19, at 11 days and clinical outcomes at 29 days.Patients who received either bamlanivimab alone or a placebo were enrolled

Read more on cidrap.umn.edu
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA